Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Lymphoid 1Gynecologic 1

Conditions

Melanoma 3Warts 1Uveal Melanoma 1Tuberous Sclerosis 1Seizures 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell 1Lennox Gastaut Syndrome 1Hyperthermia 1Hemorrhage 1Hematologic Neoplasms 1Glioblastoma 1Epilepsies, Myoclonic 1Brain Neoplasms 1

Interventions

pembrolizumab 137Nivolumab 116Ipilimumab 68Cyclophosphamide 33Specimen Handling 31Magnetic Resonance Spectroscopy 28trametinib 23binimetinib 22fludarabine 21Interleukin-2 20dabrafenib 19relatlimab 17encorafenib 17Biopsy 17CTLA-4 Antigen 16cemiplimab 15atezolizumab 15aldesleukin 15Radiosurgery 15fludarabine phosphate 14Opdualag 14Radiotherapy 11lenvatinib 10Blood Specimen Collection 10lifileucel 9Paclitaxel 8Cisplatin 8Bevacizumab 8spartalizumab 7cobimetinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Melanoma × Solutions × 1 year × Clear all
NCT04752826 2026-02-18

MK-3475-D20

BioInvent International AB

Phase 1/2 Recruiting
176 enrolled
DermatologicGynecologicLymphoid

Melanoma, Ovarian Neoplasms, Lymphoma, T-Cell

NCT07230613 2026-02-11

NEOREM-NEO-1

UNICANCER

Phase 2 Recruiting
50 enrolled
Dermatologic

Melanoma

NCT06784648 2025-11-19

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

BioInvent International AB

Phase 1/2 Active not recruiting
35 enrolled
Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡